Related Experiment Video

Updated: Oct 9, 2026

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
07:56

Bacterial Delivery of RNAi Effectors: Transkingdom RNAi

Published on: August 18, 2010

A comparative analysis of the sensitivity of multidrug resistant (MDR) and non-MDR cells to different anthracycline

M Michieli1, A Michelutti, D Damiani

  • 1Section of Hematology, University of Udine School of Medicine, Italy.

Leukemia & Lymphoma
|February 1, 1993
PubMed

Insights

Multidrug resistance (MDR) impacts cancer treatment. Overexpression of P170 glycoprotein confers resistance to classic anthracyclines like Daunorubicin and Doxorubicin, but not to lipophilic derivatives Idarubicin and Iododoxorubicin.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Tumor cell sensitivity to cytotoxic agents is crucial for effective cancer treatment.
  • Anthracyclines are widely used in treating leukemia, lymphoma, and other cancers.
  • Overexpression of the mdr-1 gene-coded P170 glycoprotein reduces cell sensitivity to anthracyclines, contributing to multidrug resistance (MDR).

Purpose of the Study:

  • To investigate the relationship between P170 glycoprotein overexpression and the cytotoxicity of classic anthracyclines (Daunorubicin, Doxorubicin) and lipophilic anthracycline derivatives (Idarubicin, Iododoxorubicin).

Main Methods:

  • Utilized multidrug resistant (MDR) and non-MDR tumor and leukemia cell lines.
  • Employed the MTT-microcultured tetrazolium colorimetric assay to assess cytotoxicity.
  • Evaluated the impact of mdr-1 gene overexpression on drug sensitivity.

Main Results:

  • mdr-1 gene overexpression strongly correlated with high-level resistance to Daunorubicin (DNR) and Doxorubicin (DX).
  • No significant resistance was observed for the lipophilic derivatives Idarubicin (IDA) and Iododoxorubicin (IDX) in the presence of mdr-1 overexpression.
  • This suggests differential sensitivity of MDR cells to various anthracyclines based on lipophilicity.

Conclusions:

  • Lipophilic anthracycline derivatives like Idarubicin and Iododoxorubicin may retain activity in multidrug resistant (MDR) cancer cell systems.
  • These findings suggest potential therapeutic strategies utilizing lipophilic anthracyclines in MDR cancers.
  • Further research into lipophilic anthracycline derivatives is warranted for overcoming anthracycline resistance.

More Related Videos

Assay Development for High-Throughput Drug Screening Against Mycobacteria07:50

Assay Development for High-Throughput Drug Screening Against Mycobacteria

Published on: October 25, 2024

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells12:25

Epigenome-Wide CRISPR-Cas9-Based Knockout Screens on Chemoresistant Cells

Published on: July 21, 2026

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...